| Patient | Harriet Tubman |
|---|---|
| Date of birth | 1822-03-01 |
| Identifiers | MRN HR-NI005-SYN-TD; SSN (made up) 000-05-3961 |
| Document date | 1897-08-17 |
| Author | Carmen Ruiz-Delgado, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month sleepiness and headache review. [S]
Mrs. Tubman returns three months after starting modafinil and increasing candesartan to 16 mg. She takes modafinil each morning and two scheduled 15-minute naps, and unplanned sleep episodes are now rare, only while seated. Her headache diary shows 21 headache days in the past three months, against 54 before treatment. She uses acetaminophen about once a week and has taken no ibuprofen. She has had no palpitations, insomnia, or loss of appetite on modafinil and no dizziness on candesartan. She is back to running her household and her church work. [S]
| Element | Detail |
|---|---|
| Sleep episodes | Rare and only while seated, with two planned naps a day |
| Headache diary | 21 headache days in three months, down from 54 |
| Acute medicine | Acetaminophen about once a week; no ibuprofen |
| Medication tolerance | No palpitations, insomnia, or appetite loss on modafinil; no dizziness on candesartan |
| Function | Running her household and church work again |
| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Headaches about seven days a month; rare sleep episodes |
| Cardiovascular | Negative | No palpitations, chest pain, or light-headedness |
| Gastrointestinal | Negative | Appetite normal; no nausea |
| Psychiatric | Negative | Mood good; no anxiety or insomnia; PHQ-9 score 2 |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ibuprofen 200 mg oral tablet, two tablets by mouth most days (self-directed, over the counter) | Two tablets by mouth most days | Oral route | 1896-09-01 to 1897-04-06 | stopped | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth as needed for headache, no more than 2 days a week | Two tablets by mouth as needed, at most 2 days a week | Oral route | 1897-04-06 | active | S |
| Candesartan 8 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1897-04-20 to 1897-05-18 | completed | S |
| Candesartan 16 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1897-05-18 | active | S |
| Modafinil 100 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 1897-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1897-08-17 | Body height | 152 | cm | S |
| 1897-08-17 | Body weight | 51.5 | kg | S |
| 1897-08-17 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 1897-08-17 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1897-08-17 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1897-08-17 | Heart rate | 76 | /min | S |
| 1897-08-17 | Respiratory rate | 14 | /min | S |
| 1897-08-17 | Body temperature | 36.6 | Cel | S |
| 1897-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1897-08-17 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1897-08-17 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1897-08-17 | Creatinine [Mass/volume] in Serum or Plasma | 0.88 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1897-08-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1892)/1.73 sq M | 68 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1897-08-17 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 1897-08-17 | PROMIS sleep related impairment - version 1.0 Tscore | 55 | {score} | S | ||
| 1897-08-17 | On how many days in the last 3 months did you have a headache, if headache lasted more than 1 day, count each day [PhenX] | 21 | {days} | S | ||
| 1897-08-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S |
Vital signs recorded on 1897-08-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and well; no spell during the visit |
| Cardiovascular | Regular rhythm; no edema |
| Neurological | Nonfocal; gait normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent sudden sleep episodes since an adolescent traumatic brain injury; narcolepsy without cataplexy due to a medical condition, provisional; historical cause retrospectively disputed | active | provisional | G47.429 | S — Synthetic diagnosis from the modern sleep testing; it echoes, but does not confirm, the R proposal of post-traumatic narcolepsy. |
| Chronic post-traumatic headache since an adolescent head injury | active | confirmed | G44.329 | S — Synthetic modern coding of the documented lifelong headaches. |
| Medication-overuse headache from near-daily ibuprofen, resolved after withdrawal | resolved | confirmed | G44.40 | S — Synthetic finding; resolved by the three-month review. |
| Sequelae of a traumatic brain injury in adolescence, a skull fracture by historical account | active | confirmed | S06.9XAS | S — Synthetic modern coding of the documented injury; the MRI findings in the episode are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PROMIS sleep-related impairment | At baseline and after treatment | Completed today | T-score 55, down 13 points from baseline |
| Medication safety | Modafinil: blood pressure and heart rate | Before starting and at follow-up | Completed today | 124/74 mmHg and pulse 76, against 132/80 and 72 before starting |
| Survey | Headache days per three months | 2 to 3 months after starting prevention | Completed today | 21, down from 54 |
| Laboratory | Basic metabolic panel (potassium and creatinine) on candesartan | Before starting and a few weeks after; then periodically | Completed today | Potassium 4.5, creatinine 0.88, eGFR 68, sodium and glucose normal |
| Laboratory | Potassium and creatinine after the candesartan dose increase | A few weeks after a dose increase | Deferred | Not drawn after the dose was doubled three months ago, a gap in usual practice for angiotensin receptor blockers. Today's potassium and creatinine are normal, so no harm resulted. Future dose changes will carry a check in two to four weeks |
| Examination | Blood pressure, heart rate, and weight | Every visit | Completed today | 124/74 mmHg, pulse 76, weight 51.5 kg |
| Self-management | Headache diary (headache days and acute-medicine days) | Daily | Completed today | Reviewed; about seven headache days a month |
| Medication safety | Acute headache medicine on no more than 2 days a week | Every visit | Completed today | Acetaminophen about once a week; no NSAIDs |
| Survey | Depression screen (PHQ-9) | At baseline and at follow-up | Completed today | Score 2 |
| Self-management | Safety advice for sudden sleep episodes | Every visit | Completed today | Reviewed; no episodes while standing, walking, or cooking since starting modafinil |
Goal progress:
Guideline basis: Evidence-based guideline: Management of an unprovoked first seizure in adults (Krumholz A, et al. Neurology 2015;84(16):1705-1713) (2015); Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline (Maski K, et al. J Clin Sleep Med 2021;17(9):1881-1893) (2021); The International Classification of Headache Disorders, 3rd edition (Cephalalgia 2018;38(1):1-211) (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (Ailani J, et al. Headache 2021;61(7):1021-1039) (2021)
Follow-up: Annual wellness visit in the fall. Continue the headache diary and scheduled naps. Next scheduled visit 1897-10-13: subsequent annual wellness visit. [S]